Yuichiro Ohe
Computer Vision and Pattern Recognition · 2005–2022
A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Computer Vision and Pattern Recognition — 8 citations into it
Whom Yuichiro Ohe trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Ning Qian (in Optimization & Training)
- Karen Simonyan (in Computer Vision and Pattern Recognition)
- Andrew Zisserman (in Computer Vision and Pattern Recognition)
Papers from Yuichiro Ohe's perspective
Ordered by how strongly the researchers Yuichiro Ohe trusts endorse each paper. Same corpus, a different order for every researcher.
- Rich Feature Hierarchies for Accurate Object Detection and Semantic Segmentation
- Very Deep Convolutional Networks for Large-Scale Image Recognition (International Conference on Learning Representations)
- SSD: Single Shot MultiBox Detector
- Chainer : a Next-Generation Open Source Framework for Deep Learning
- Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. (Journal of Clinical Oncology)
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised… (The Lancet Oncology)
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity (Clinical Cancer Research)
- On the momentum term in gradient descent learning algorithms
- Dermatologist-level classification of skin cancer with deep neural networks
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase… (The Lancet Oncology)
Their papers
- Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. (2006) — 645 citations
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial (2022)
- The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning (2020) — 236 citations
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. (2019) — 2,401 citations
- Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018) — 4,506 citations
- AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015) — 1,903 citations
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. (2009) — 1,152 citations
- Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. (2005) — 706 citations